Understanding why cancer immunotherapy helps some people but causes side effects in others

MANIFEST: Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN90482257

Enrollment

3000

Registered

2026-04-24

Start date

2026-02-04

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosocial oncology and survivorship Cancer

Interventions

MANIFEST is an observational research study. It will involve patients who are receiving immunotherapy as part of their planned cancer treatment at NHS hospitals - the study will not change or interfer

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Written or electronic informed consent 2. Age 18 years or older 3. Confirmed diagnosis of a solid organ malignancy with a clinical indication and appropriate treatment plan to commence an immunotherapy either as standard of care or as part of a clinical trial with/without the use of investigational agents

Exclusion criteria

Exclusion criteria: 1. Medical or psychological condition that would preclude informed consent 2. Subjects unable to comply with the study or sample schedule

Countries

England, United Kingdom

Contacts

Public ContactKate Brown

the-christie.manifest-study@nhs.net-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026